CJC-1295 no DAC 5mg + IPA 5mg

For laboratory research use only by qualified professionals. Not for human or veterinary use. Not for ingestion, injection, topical application, diagnostic, therapeutic, prophylactic or cosmetic use.

CJC-1295 no DAC 5 mg + Ipamorelin 5 mg is supplied as a catalogued research material in 10 mg total nominal catalogue presentation: 5 mg + 5 mg. It is intended only for controlled analytical, biochemical and non-clinical laboratory workflows. The catalogue amount identifies the nominal vial presentation; it is not a dose or a use instruction.

This product is a mixture and has no single formula, mass or registry identifier. The exact CJC no-DAC species, both component salt forms and the catalogue-stated 5 mg + 5 mg ratio require confirmation in the matching CoA [1–4].

Product identity

Identity must be assigned to the exact batch rather than to a marketed name alone. Sequence, terminal modifications, conjugation, salt or counter-ion, hydration state and excipients may change the applicable mass and registry identifiers. The batch CoA and SDS take precedence over literature identifiers shown below.

Chemical properties and registry information

Where an identifier is qualified or omitted, no unambiguous exact-form public assignment has been confirmed. Do not transfer an identifier from a related analogue, salt, conjugate or formulation.

Research context and evidence status

What the literature supports

Modified GRF species and ipamorelin have been studied separately in receptor, signaling, analytical and investigational pharmacology research; this does not create evidence for the combined mixture [1–4].

Evidence limitations

No controlled blend-specific human evidence was identified. Human CJC-1295 studies commonly concern the DAC conjugate, while ipamorelin studies concern separately manufactured material; neither can be transferred to this blend.

“10 mg total” is a nominal two-component catalogue presentation, not the molecular mass of one substance or a dose.

Technical comparison

The comparison below is limited to structural and analytical distinctions. It does not compare clinical performance or recommend a use.

Quality and batch documentation

Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.

Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.

Laboratory handling and storage

Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.

This page intentionally provides no reconstitution, administration or dosing instructions. Laboratory preparation, analytical method selection, risk assessment, personal protective equipment and waste disposal must be defined by the qualified institution and the applicable SDS.

Regulatory and legal status

This catalogue material is not offered as a medicine, medical device, in-vitro diagnostic, food, dietary supplement, cosmetic or veterinary product. It is not intended to diagnose, treat, cure, mitigate or prevent any disease or condition.

A research designation does not override medicinal-product, controlled-substance, chemical, customs or other substance-specific rules. Availability may be restricted by jurisdiction and by the purchaser's verified professional or institutional status.

Sources and references

References document identity and research context only. They do not constitute instructions for use or evidence that this catalogue batch is suitable for any human or veterinary purpose.

1. [1] U.S. FDA. Identity review of CJC-1295-related substances and DAC/no-DAC distinctions.
2. [2] Timms et al. LC–MS characterization of CJC-1295-related peptide species (2019).
3. [3] PubChem. Ipamorelin, CID 9831659.
4. [4] U.S. FDA. Identity, safety and evidence review of ipamorelin.

Frequently Asked Questions

What is this material intended for?

Controlled laboratory research by qualified professionals, including substantiated analytical, biochemical or non-clinical workflows. It is not intended for personal use.

Is the amount shown on the vial a dosage?

No. It is a nominal catalogue presentation used to identify the product variant. It is not a dose, concentration, administration schedule or preparation instruction.

Do the CAS number and PubChem CID apply to every batch form?

Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.

What does an analytical purity result mean?

It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.

How should the material be stored and handled?

Follow the exact label, batch CoA and SDS, together with the institution's risk assessment. This page does not provide reconstitution or administration guidance.

May this material be used in humans or animals?

No. Human and veterinary use, including ingestion, injection, topical application, diagnosis, treatment, prevention and cosmetic use, is expressly excluded.

RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. THE PRODUCT NAME, VIAL AMOUNT AND LITERATURE REFERENCES MUST NOT BE INTERPRETED AS A DOSAGE, ADMINISTRATION INSTRUCTION OR MEDICAL CLAIM.